Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.
Front Immunol. 2023 Mar 13;14:1112750. doi: 10.3389/fimmu.2023.1112750. eCollection 2023.
The incidence rate and mortality rate of cervical cancer have steadily increased in young women in China. Therefore, it is critical to improve HPV vaccination rates, particularly for the younger population. There are currently five types of prophylactic vaccines in China: bivalent HPV vaccine (AS04-HPV-16/18), quadrivalent HPV vaccine, 9-valent HPV vaccine, homemade Escherichia coli-produced HPV bivalent vaccine, and Pichia pastoris produced HPV bivalent vaccine. All these five HPV vaccines have completed relevant clinical trials in China, and have been proven to be generally well-tolerated and immunogenic, efficacious against persistent HPV-related infections and genital precancerous lesions (data for 9-valent HPV vaccine is absent), and have demonstrated acceptable safety profiles, as previously shown in global studies. Given that the HPV vaccination rate in China is still very low, additional HPV vaccine coverage is needed to reduce the incidence and mortality rates of cervical cancer.
在中国，宫颈癌的发病率和死亡率在年轻女性中稳步上升。因此，提高 HPV 疫苗接种率至关重要，特别是针对年轻人群。目前中国有五种预防性疫苗：二价 HPV 疫苗（AS04-HPV-16/18）、四价 HPV 疫苗、九价 HPV 疫苗、大肠杆菌生产的国产二价 HPV 疫苗和毕赤酵母生产的国产二价 HPV 疫苗。所有这五种 HPV 疫苗均已在中国完成相关临床试验，证明其一般具有良好的耐受性和免疫原性，对持续性 HPV 相关感染和生殖器癌前病变具有疗效（九价 HPV 疫苗的数据缺失），并具有可接受的安全性，此前在全球研究中已有显示。鉴于中国 HPV 疫苗接种率仍然很低，需要增加 HPV 疫苗接种覆盖率，以降低宫颈癌的发病率和死亡率。
